Table 1.
Mannheim Cohort |
MD Anderson Cohort |
P | |||
---|---|---|---|---|---|
n or median | percentage/range | n or median | percentage/range | ||
Age, y | 66.6 | 45.4-92.1 | 67.4 | 41.0-90.6 | 0.72 |
≥75 | 21 | 20.6 | 9 | 15.7 | 0.53 |
<75 | 81 | 79.4 | 48 | 84.2 | |
Gender | |||||
Male | 77 | 75.5 | 49 | 86.0 | 0.29 |
Female | 25 | 24.5 | 8 | 14.0 | |
Tumor stage | |||||
pT1 | 2 | 2.0 | 2 | 3.5 | 0.51 |
pT2 | 24 | 23.5 | 12 | 21.1 | |
pT3 | 56 | 53.9 | 35 | 61.4 | |
pT4 | 20 | 19.6 | 8 | 14.0 | |
CIS | 0 | 0 | 0 | 0 | |
pT4 or pN+ | 47 | 46.1 | 39 | 68.4 | 0.001 |
Nodal stage | |||||
pN0 | 65 | 63.7 | 22 | 38.6 | 0.002 |
pN1 | 12 | 11.8 | 9 | 15.8 | |
pN2 | 25 | 24.5 | 26 | 45.6 | |
Grading | |||||
G3 | 82 | 80.5 | n.a. | n.a. | |
G2 | 19 | 18.6 | n.a. | n.a. | |
G1 | 1 | 0.9 | n.a. | n.a. | |
Concomitant carcinoma in situ | 23 | 22.5 | n.a. | n.a. | |
Chemotherapy | |||||
Neo-adjuvant | 0 | 0 | 20 | 35.0 | <0.001 |
Adjuvant | 12 | 14.8 | n.a. | n.a. | |
Outcome | |||||
Follow-up | 20.8 | 3.6-179.2 | 38.1 | 3.9-180 | 0.63 |
Cancer-specific death | 50 | 49.0 | 17 | 30.0 | 0.01 |
Time to Cancer-specific death, months | 17.6 | 3.1-86.5 | 24.2 | 4.8-79.2 | 0.17 |